21,223 active cure trials; 13 new signals in 24h
LISTEN
Direct audio file (MP3)The cure pipeline remains crowded and accelerating: 21,223 active cure-related trials are underway globally, with 13 new Wire signals and 4 new Cure research updates added in the last 24 hours. Among the most consequential developments, Nature Medicine reports an ImmunoPRISM randomized phase 2 trial in high-risk smoldering multiple myeloma where teclistamab outperforms the comparator regimen. Separately, Nature Biotechnology highlights AI-guided design that “closes the loop” to generate complete bacteriophage genomes, and reports engineered bacteria capable of on-demand glycemic control—two examples of platform capability turning into medical-grade function. Moderna’s flu vaccine also received FDA approval, reinforcing that AI-enabled and modernized biomedical approaches can translate into regulated, scalable interventions. The window is still open.
ImmunoPRISM is a Nature Medicine–reported randomized phase 2 trial where teclistamab shows higher efficacy than lenalidomide-dexamethasone in high-risk smoldering multiple myeloma.
Patients with high-risk smoldering multiple myeloma gain a potential earlier, more effective disease-control strategy, while platform advances in synthetic biology and AI design expand the menu of future cures across conditions.
Watch for replication and outcome details from ImmunoPRISM alongside follow-through on the phage-genome and engineered-bacteria platforms, because the next translation steps will determine whether today’s signals become tomorrow’s standards.